Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Laser vision correction enhancement after scleral implants for the treatment of presbyopia: patient follow-up

Poster Details

First Author: J.Katz USA

Co Author(s):                        

Abstract Details

Purpose:

To examine postoperative near visual acuity outcomes of eyes that have previously received VisAbility�â�„�¢ Micro-inserts (Refocus Group, Dallas, TX) for presbyopia correction and have opted to undergo Laser Vision Correction to neutralize unwanted refractive error (i.e. hyperopia with or without astigmatism) in an effort to achieve better Uncorrected Near Visual Acuity.

Setting:

The Midwest Center for SightChicago, IL USA

Methods:

Eleven patients who had completed a IDE clinical trial that ended in 2015 in which they received either unilateral or bilateral Scleral Spacing Procedure (SSP) to improve near visual acuity elected to undergo Laser Vision Correction (LVC). Visual acuity was measured at baseline (pre-LVC), and followed through 6 months postop.

Results:

Twenty-two eyes of 11 patients that implanted with VisAbility�â�„�¢ Implants and underwent LVC have been followed for 6 months to date. The mean lines of improvement (UCNVA) were 3.1 (�.59 SD, range; 1-5 lines) at 3 months and 2.9 (�.25 SD, range; 1-5 lines) at 6 months post op. At pre-op, none of the patients were J1 or better (UCNVA), 14% (3/22) were J2 or better, and 18% (4/22) were J3 or better. For patient UCNVA at 6 months post-op, 55% (12/22) were J1 or better, 77% (17/22) were J2 or better, and 95% (21/22) were J3 or better.

Conclusions:

This examination of patients with VisAbility�â�„�¢ Micro Insert procedure that subsequently elect to undergo LVC suggests that the combination of procedures may provide correction of near vision with corresponding reduction in the amount of refraction needed to achieve optimal UCNVA.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing